^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
budigalimab (ABBV-181)
i
Other names: ABBV-181, ABBV 181, ABBV181
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie
Drug class:
PD1 inhibitor
Related drugs:
1m
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (clinicaltrials.gov)
P2, N=150, Not yet recruiting, AbbVie
New P2 trial
|
gemcitabine • paclitaxel • docetaxel • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
2ms
AndroMETa-GEA: A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (clinicaltrials.gov)
P2, N=180, Not yet recruiting, AbbVie
New P2 trial
|
5-fluorouracil • oxaliplatin • budigalimab (ABBV-181) • leucovorin calcium • telisotuzumab adizutecan (ABBV-400)
2ms
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis (clinicaltrials.gov)
P1/2, N=40, Terminated, AbbVie | Completed --> Terminated; Strategic considerations
Trial termination
|
5-fluorouracil • oxaliplatin • irinotecan • budigalimab (ABBV-181) • leucovorin calcium • giloralimab (ABBV-927)
2ms
LIVIGNO-1: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
P2, N=130, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
Enrollment closed • Adverse events • Combination therapy • Checkpoint inhibition • Metastases
|
sorafenib • Lenvima (lenvatinib) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
2ms
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382 (clinicaltrials.gov)
P2, N=160, Recruiting, AbbVie | Trial completion date: Oct 2026 --> Mar 2027 | Trial primary completion date: Apr 2025 --> Mar 2027
Trial completion date • Trial primary completion date • Adverse events
|
CD4 (CD4 Molecule)
|
budigalimab (ABBV-181)
2ms
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
P1, N=20, Recruiting, AbbVie | Not yet recruiting --> Recruiting
Enrollment open • Adverse events • Combination therapy • Checkpoint inhibition • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
3ms
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=150, Active, not recruiting, AbbVie | Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: Sep 2024 --> Mar 2025
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
4ms
Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer (ESMO 2024)
HLA-DQ is an HLA class II molecule expressed on APCs. Patients were enrolled May 2020 to Feb 2022 and treated with standard dosing of G/nP (d1, 8, 15) and either TTX-030 40mg/kg followed by 20mg/kg every two weeks (n = 31) or TTX-030 every 2 weeks and budigalimab (anti-PD1 Ab) 500mg every 4 weeks (n = 28). TTX-030 combinations show promising clinical activity in 1L PDAC with HLA-DQhigh having marked benefit. A randomized phase 2 study (NCT06119217) is underway to further evaluate TTX-030 combination treatment based on HLA-DQ status in metastatic PDAC.
Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
nCounter® PanCancer Immune Profiling Panel
|
budigalimab (ABBV-181) • TTX-030
5ms
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
P1, N=20, Not yet recruiting, AbbVie
New P1 trial • Adverse events • Combination therapy • Checkpoint inhibition • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
5ms
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=163, Active, not recruiting, AbbVie | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
Trial completion date • Trial primary completion date • Metastases
|
budigalimab (ABBV-181) • giloralimab (ABBV-927)
6ms
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=150, Active, not recruiting, AbbVie | Trial completion date: Nov 2023 --> Sep 2024 | Trial primary completion date: Nov 2023 --> Sep 2024
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PD-L1 negative
|
carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
7ms
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=350, Recruiting, AbbVie | Trial completion date: Oct 2025 --> May 2027
Trial completion date • Adverse events • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
|
EGFR mutation • IDH wild-type • SEZ6 expression
|
cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
7ms
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis (clinicaltrials.gov)
P1/2, N=40, Completed, AbbVie | Active, not recruiting --> Completed | Phase classification: P1b/2 --> P1/2
Trial completion • Phase classification • Adverse events • Combination therapy • Metastases
|
5-fluorouracil • oxaliplatin • irinotecan • budigalimab (ABBV-181) • leucovorin calcium • giloralimab (ABBV-927)
7ms
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 (clinicaltrials.gov)
P2, N=140, Recruiting, AbbVie | Trial completion date: Nov 2025 --> Oct 2026
Trial completion date • Adverse events
|
CD4 (CD4 Molecule)
|
budigalimab (ABBV-181)
7ms
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=362, Recruiting, AbbVie | Trial primary completion date: Feb 2026 --> Jun 2027
Trial primary completion date • Combination therapy • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
7ms
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers (clinicaltrials.gov)
P1, N=185, Completed, Trishula Therapeutics, Inc. | Active, not recruiting --> Completed
Trial completion • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • gemcitabine • docetaxel • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • budigalimab (ABBV-181) • leucovorin calcium • TTX-030
8ms
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=350, Recruiting, AbbVie | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Dec 2026 --> Oct 2025
Trial completion date • Trial primary completion date • Adverse events • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
|
EGFR mutation • IDH wild-type • SEZ6 expression
|
cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
8ms
LIVIGNO-4: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
P2/3, N=840, Recruiting, AbbVie | Not yet recruiting --> Recruiting
Enrollment open • Adverse events • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
8ms
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients (clinicaltrials.gov)
P2, N=180, Recruiting, Trishula Therapeutics, Inc. | Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Mar 2024
Enrollment open • Trial initiation date • Metastases
|
gemcitabine • albumin-bound paclitaxel • budigalimab (ABBV-181) • TTX-030
8ms
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=337, Recruiting, AbbVie | Trial completion date: Feb 2026 --> Jun 2027
Trial completion date • Combination therapy • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
9ms
LIVIGNO-4: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
P2/3, N=840, Not yet recruiting, AbbVie
New P2/3 trial • Adverse events • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
9ms
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=132, Completed, AbbVie | Active, not recruiting --> Completed
Trial completion
|
SEZ6 (Seizure Related 6 Homolog)
|
budigalimab (ABBV-181) • ABBV-011
9ms
A Study of Adverse Events, How Intravenously (IV) Infused ABBV-303 Moves Through the Body, and Change in Disease State, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=181, Recruiting, AbbVie | Not yet recruiting --> Recruiting
Enrollment open
|
budigalimab (ABBV-181)
11ms
LIVIGNO-2: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
P2/3, N=660, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Phase classification: P2 --> P2/3
Enrollment open • Phase classification • Adverse events • Combination therapy • Metastases
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
12ms
A Study of Adverse Events, How Intravenously (IV) Infused ABBV-303 Moves Through the Body, and Change in Disease State, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=181, Not yet recruiting, AbbVie
New P1 trial • Adverse events • Combination therapy • Pan tumor • Metastases
|
budigalimab (ABBV-181)
1year
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients (clinicaltrials.gov)
P2, N=180, Not yet recruiting, Trishula Therapeutics, Inc.
New P2 trial • Metastases
|
gemcitabine • albumin-bound paclitaxel • budigalimab (ABBV-181) • TTX-030
1year
LIVIGNO-2: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
P2, N=660, Not yet recruiting, AbbVie
New P2 trial • Adverse events • Combination therapy • Metastases
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
1year
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=337, Recruiting, AbbVie | Trial completion date: Apr 2024 --> Feb 2026 | Trial primary completion date: Apr 2024 --> Feb 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
1year
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 (clinicaltrials.gov)
P2, N=140, Recruiting, AbbVie | Not yet recruiting --> Recruiting
Enrollment open • Adverse events
|
CD4 (CD4 Molecule)
|
budigalimab (ABBV-181)
over1year
Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors (ESMO 2023)
The study will evaluate the preliminary safety, tolerability, pharmacokinetics (PK), and antitumor activity of ABBV-706 as monotherapy and in combination with budigalimab (a PD-1 inhibitor), carboplatin, or cisplatin, and determine the recommended phase 2 dose (RP2D) of ABBV-706. Tumor tissue submission for retrospective SEZ6 expression analysis is required. The study began in December 2022 and enrollment is ongoing.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
SEZ6 (Seizure Related 6 Homolog)
|
SEZ6 expression
|
cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
over1year
First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors (ESMO 2023)
In dose expansion, patients with R/R non-small cell lung cancer will be enrolled in ABBV-514 monotherapy (N=12) and ABBV-514 + BDG (N=12) cohorts, and patients with R/R head and neck squamous cell carcinoma in an ABBV-514 + BDG (N=12) cohort. Enrollment initiated in November 2021, with 30 patients enrolled as of April 2023.
Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CCR8 (C-C Motif Chemokine Receptor 8)
|
budigalimab (ABBV-181) • ABBV-514
over1year
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis (clinicaltrials.gov)
P1b/2, N=129, Recruiting, AbbVie | Trial completion date: Jun 2025 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Adverse events • Combination therapy • Metastases
|
5-fluorouracil • oxaliplatin • irinotecan • budigalimab (ABBV-181) • leucovorin calcium • giloralimab (ABBV-927)
over1year
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=132, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | N=233 --> 132
Enrollment closed • Enrollment change • Combination therapy
|
budigalimab (ABBV-181) • ABBV-011
almost2years
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=150, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PD-L1 negative
|
carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
almost2years
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=350, Recruiting, AbbVie | Not yet recruiting --> Recruiting
Enrollment open • Adverse events • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • IDH wild-type
|
cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
2years
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=350, Not yet recruiting, AbbVie
New P1 trial • Adverse events • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • IDH wild-type
|
cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
2years
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=150, Recruiting, AbbVie | Trial completion date: Jul 2024 --> Nov 2023
Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PD-L1 negative
|
carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
over2years
Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. (PubMed, Ann Oncol)
We demonstrate that baseline ARG levels predict ICI response. Plasma ARG quantification may therefore represent an attractive biomarker to tailor novel therapeutic regimens targeting the ARG pathway in combination with ICIs.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
budigalimab (ABBV-181)
over2years
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=150, Recruiting, AbbVie | Trial completion date: Dec 2023 --> Jul 2024
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PD-L1 negative
|
carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)
over2years
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=139, Completed, AbbVie | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
budigalimab (ABBV-181) • revdofilimab (ABBV-368)
over2years
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=182, Completed, AbbVie | Active, not recruiting --> Completed
Trial completion • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Venclexta (venetoclax) • budigalimab (ABBV-181) • Rova-T (rovalpituzumab tesirine)
over2years
Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer (AACR 2022)
The addition of nivolumab to chemotherapy has recently become the standard of care of 1st‑line (1L) treatment of locally advanced or metastatic (LA/M) gastric cancer but further improvements are needed. An expansion cohort of Study TTX‑030‑002 (ongoing, US and South Korea) is evaluating the safety and efficacy of the combination of TTX-030, budigalimab (anti-PD-1) and FOLFOX for the 1L treatment of patients (pts) with LA/M HER2− gastric/GEJ adenocarcinoma... Preliminary results indicate that the combination of TTX-030, budigalimab and FOLFOX exhibited promising efficacy as 1L treatment of LA/M gastric/GEJ cancer regardless of CPS status and has a manageable safety profile without evidence of excessive toxicities. To our knowledge, this represents the first report of an anti-CD39 antibody in combination with chemo-immunotherapy in gastric cancer. Updated clinical and biomarker data will be included in the final presentation.
Clinical • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
Opdivo (nivolumab) • 5-fluorouracil • budigalimab (ABBV-181) • leucovorin calcium • TTX-030
Share via
